CYT-538 / Cytovia Therap - LARVOL DELTA

Cytovia and Cellectis Expand Their TALEN Gene-Edited iNK Partnership to Enable Broader Collaboration in China (GlobeNewswire) - "Cytovia Therapeutics...and Cellectis...announced today that they have expanded their collaboration of TALEN® gene-edited iPSC-derived NK and CAR-NK cells to include new CAR target and development in China by Cytovia’s joint venture entity, CytoLynx Therapeutics. The amended financial terms include an equity stake totaling $20 million in Cytovia stock as well as up to $805 million of development, regulatory, and sales milestones and single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia."

Licensing / partnership • Oncology